http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201332548-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 |
| filingDate | 2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a974c6e390f489aab2f832601c55ce |
| publicationDate | 2013-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201332548-A |
| titleOfInvention | N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzoic acid for the treatment of chronic myelogenous leukemia Guanamine |
| abstract | The present invention relates to a method for treating chronic myelogenous leukemia in a subject, which comprises administering to the subject a compound which inhibits the T3151 mutation of BCR-ABL tyrosine kinase, such as N-methyl-2-[3-((E)-2 - Pyridin-2-yl-vinyl)-1H-indazol-6-ylhydrothio]-benzamide or a pharmaceutically acceptable salt thereof. The invention also relates to compounds comprising a T315l mutation which inhibits BCR-ABL tyrosine kinase, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indole A pharmaceutical composition of oxazol-6-ylhydrothio]-benzamide or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. |
| priorityDate | 2011-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.